Exon 19 mutations characterized ... However, activation of the Ras–MAPK pathway has not been as well correlated with response to EGFR inhibitors as the PI3K–Akt pathway 158.

AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib ... AKT1, or PTEN mutations. It can be used in patients whose disease has progressed despite prior ...